REGN
Regeneron Pharmaceuticals Inc
796.00$
-0.7%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +37.3% | +15.4% | -9.7% | +71.8% | -62.9% | +0.1% | +161.5% | +202.7% | -62.0% | -4.1% | +97.1% | +90.7% | +59.1% | +21.0% | -2.9% | +209.2% | +52.7% | +34.0% | +45.5% | +18.4% | +20.8% | +14.3% | +17.2% | +8.1% | +89.1% | -24.3% | +7.8% | +8.3% | +1.0% | |
| – | +136.4% | +92.3% | -28.0% | +332.4% | -58.2% | -0.4% | +3.0% | +2,166.5% | -83.4% | -9.3% | +902.7% | -99.6% | +1,626.2% | -86.9% | +101.4% | +1,903.2% | +84.0% | +32.0% | +91.5% | -23.7% | +32.5% | +9.3% | +80.2% | +73.3% | +100.9% | -37.4% | -48.2% | +123.0% | +6.6% | |
| – | +32.6% | +8.9% | -6.9% | +41.5% | -64.6% | +0.3% | +227.8% | -55.3% | +81.1% | -1.0% | +207.1% | +90.0% | +53.0% | +25.8% | -3.4% | +193.0% | +50.6% | +34.1% | +41.9% | +22.9% | +20.1% | +14.6% | +12.8% | +0.8% | +86.9% | -21.6% | +16.9% | 0.0% | +0.1% | |
| – | -1.8% | +33.1% | +21.4% | +25.3% | +62.7% | +36.5% | +8.9% | +0.1% | +1.3% | -11.5% | +55.7% | +46.2% | +38.3% | +27.2% | +8.2% | +18.1% | +37.5% | +47.8% | +27.5% | +26.6% | +1.1% | +5.3% | +38.9% | -17.7% | +4.9% | +16.6% | +45.3% | +17.9% | +11.8% | |
| – | -1.7% | +0.0% | +10.3% | +29.8% | +15.6% | +30.4% | +18.0% | +15.4% | +49.3% | +1.6% | +46.2% | +30.3% | +7.2% | +23.2% | +79.8% | +79.7% | +56.3% | +53.2% | +66.1% | +40.4% | +12.1% | +17.9% | +17.9% | -26.6% | +35.6% | +15.9% | +20.7% | +15.7% | -8.6% | |
| – | -5.7% | +20.5% | +19.4% | +26.1% | +46.6% | +35.9% | +9.7% | -88.7% | +857.3% | -9.4% | +54.0% | +43.6% | +33.6% | +26.8% | +16.6% | +29.3% | +42.2% | +49.3% | +38.5% | +31.3% | +5.1% | +10.2% | +30.2% | -26.8% | +23.5% | +15.5% | +39.1% | +16.6% | +5.1% | |
| – | – | – | – | – | – | – | – | – | -2,303.7% | – | – | – | – | – | – | – | +66.0% | +10.3% | +49.3% | +6.3% | +56.3% | +21.9% | -12.8% | +61.9% | +150.1% | -39.8% | -24.9% | -1.4% | -10.3% | |
| – | -76.2% | +29.4% | -77.3% | +357.5% | +165.8% | -22.4% | -52.7% | +980.9% | -14.9% | -59.7% | -27.2% | -35.6% | -69.9% | +290.2% | +133.4% | +112.9% | +2.5% | -19.5% | -61.9% | -49.5% | +249.1% | +12.3% | +7.1% | +88.4% | +0.7% | +3.7% | +22.9% | -24.4% | -20.7% | |
| – | – | – | – | – | – | – | – | – | +130.9% | -173.2% | – | – | – | – | – | – | +72.1% | +8.7% | +57.9% | +8.5% | +56.3% | +22.9% | -4.9% | +56.9% | +144.7% | -47.9% | -13.6% | +13.8% | +9.4% | |
| – | -74.5% | -212.0% | – | – | -961.7% | – | – | -2,901.9% | – | -112.2% | – | – | -275.3% | – | – | – | – | +48.0% | +37.7% | -26.3% | +102.6% | -87.6% | +187.2% | -5.1% | +320.8% | -58.4% | -52.8% | +49.5% | +97.6% | |
| – | – | – | – | – | – | – | – | – | -328.9% | – | – | – | – | – | – | – | -43.4% | -18.0% | +82.7% | +40.8% | +33.8% | +104.0% | -13.4% | +66.0% | +129.9% | -46.3% | -8.9% | +11.6% | +2.1% | |
| – | – | – | – | – | – | – | – | – | -198.1% | – | – | – | – | – | – | – | +62.0% | +11.2% | +48.9% | +8.2% | +55.0% | +20.6% | -9.8% | +69.5% | +135.7% | -45.6% | -23.1% | +31.4% | +9.4% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.